Protein Kinase C (19-31) (TFA) ( PKC (19-31) (TFA) )

产品货号. M29751 CAS No. ——

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

产品询价大包装询价加入购物车

产品名称

Protein Kinase C (19-31) (TFA)
注意事项

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断
产品简述

Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing the protein kinase C activity.
产品描述

Protein Kinase C (19-31) TFA, a peptide inhibitor of protein kinase C (PKC), derived from the pseudo-substrate regulatory domain of PKCa (residues 19-31) with a serine at position 25 replacing the wild-type alanine, is used as protein kinase C substrate peptide for testing the protein kinase C activity.
体外实验

——
体内实验

——
同义词

PKC (19-31) (TFA)
通路

Others
靶点

Other Targets
受体

——
研究领域

——
适应症

——

CAS Number

——
分子量

1657.84
分子式

C69H119F3N26O18
纯度

>98% (HPLC)
溶解度

——
SMILES

——
化学全称

Sequence:{Arg}{Phe}{Ala}{Arg}{Lys}{Gly}{Ala}{Leu}{Arg}{Gln}{Lys}{Asn}{Val}

Mellor H, et al. The extended protein kinase C superfamily. Biochem J. 1998 Jun 1;332 ( Pt 2):281-92.

计算器

产品手册

关联产品

pp60 c-src (521-533)...

Peptide corresponding to the pp60c-src carboxy terminal regulatory domain; phosphorylated at Tyr527. Binds to pp60c-src and pp60v-src at the SH2 domain, suppressing their tyrosine kinase activity and transforming potential.
Letolizumab

Letolizumab (BMS-986004) 是一种靶向 CD40L 的单克隆抗体，其产生是为了表达缺乏效应器功能的突变 IgG1，包括 Fc 结合和补体固定。Letolizumab 降低了排斥反应、血栓栓塞，延长了存活时间。
Anthranilic acid

2-氨基苯甲酸，也称为邻氨基苯甲酸盐或邻氨基苯甲酸，属于氨基苯甲酸类有机化合物。